Mydrin-P Special Precautions

Careful Administration: Mydrin-P should be administered with care in the following patients.
Children: See Use in Children as follows.
Hypertensive patients: Symptoms may be aggravated due to hypertensive effect of phenylephrine.
Patients with arteriosclerosis: Symptoms may be aggravated due to hypertensive effect of phenylephrine.
Patients with heart disease, including coronary artery disease or heart failure: Symptoms may be aggravated due to β1 agonistic effect of phenylephrine.
Patients with diabetes: Symptoms may be aggravated due to the gluconeogenesis-promoting effect of phenylephrine.
Patients with hyperthyroidism: Because hyperthyroidism may be accompanied with the development of sympathomimetic symptoms such as palpitation and tachycardia, administration of this product may aggravate these symptoms.
Important Precautions: As bradycardia, apnea, etc. may occur when this product is administered to premature infants for the purpose of funduscopy, this product should be administered with care while closely observing the patient's condition. (See Use in Children as follows.)
Since this product causes mydriasis and/or cycloplegia, patients should be cautioned against engaging in potentially hazardous activities requiring clear vision, such as operating machinery or driving a car. Instruct the patients to protect their eyes from direct sunlight or other powerful light by wearing sunglasses or by other means.
Others: Do not use this product if it is discolored or contains a precipitate.
Use in the Elderly: Because physiological function is generally reduced in the elderly, caution should be exercised.
Use in Children: Since systemic adverse reactions are likely to occur when administered to pediatric patients, this product should be administered with care while observing the patient's condition. Especially when applied to premature infants, administer cautiously under close observation of the patient's condition, since it has been reported that bradycardia, apnea or gastrointestinal hypomotility (abdominal distension, decreased milk intake, etc.) have occurred. In the case of any abnormal findings, administration should be discontinued immediately and appropriate measures should be taken. It is advisable that this product should be diluted for use, if necessary.